#$XNCR
LightNews LightNews
notreload.bsky.social
#$RZLT #$ANET #$CVCO #$CRWV #$TRAX #$FORM #$NBIS #$NUVB #$XNCR -- THE WSJ
September 30, 2026 at 1:50 PM
powerfromspace1.bsky.social
@ThePrimeTime on YT!

This is why we can’t have bad things...

www.youtube.com/watch?v=xNcr...

#SWE #Coding #FingerD #RShell #Worms

8/7/2026
The Worm that changed everything
YouTube video by The PrimeTime
www.youtube.com
August 8, 2026 at 12:20 AM
quant-hub.bsky.social
🚨 $XNCR
Montgomery Alan Bruce, a Director, filed a notice of intent to sell 5,064 shares of common stock, valued at approximately $62,337.84, on 06/15/2026.
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
June 15, 2026 at 3:36 PM
marketwirenews.com
NEWS: ( NASDAQ: #XNCR ) Xencor Announces Pricing of $175 Million Public Offering of Common Stock

#StockMarket #News
September 11, 2024 at 2:40 PM
bluefors.com
Of course a French quantum lab would name their cryostats Obélix and Idéfix🤩 Curious how they were installed? Watch the behind-the-scenes from @alice-and-bob.bsky.social:

www.youtube.com/watch?v=xNcR...

#CoolForProgress #quantum #cryogenics
Alice & Bob and Bluefors
YouTube video by Bluefors
www.youtube.com
July 29, 2025 at 12:01 PM
marketwirenews.com
News; ( NASDAQ: #XNCR ) Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

#StockMarket #News
September 9, 2024 at 2:45 PM
pdrworld.bsky.social
Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab.
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...
ClinicalTrials.gov
clinicaltrials.gov
September 4, 2024 at 11:57 AM
ytvmarketnews.bsky.social
Xencor (XNCR) Could Be 6% Below Fair Value On Its Antibody Pipeline Narrative

Xencor (XNCR) is drawing fresh attention after management scheduled a presentation at the Cantor Global Healthcare Conference on September 9, 2026, as investors watch for any updates on its antibody pipeline. The recent…
Xencor (XNCR) Could Be 6% Below Fair Value On Its Antibody Pipeline Narrative
Xencor (XNCR) is drawing fresh attention after management scheduled a presentation at the Cantor Global Healthcare Conference on September 9, 2026, as investors watch for any updates on its antibody pipeline. The recent scheduling of Xencor’s Cantor presentation comes after a sharp shift in sentiment, with the stock giving back some ground in the last week. It has a 7 day share price return of 5.41% and a 1 day share price return of 3.62%, following a strong 30 day share price return of 38.66% and a 90 day share price return of 123.98%.
ytvmarketnews.com
September 3, 2026 at 6:42 AM
spaceman-trading.bsky.social
Watchlist update (+8/-9)
Added: IMMX (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); CSTL (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); +6 more
Removed: XNCR (rotated out by dynamic screener/volatility filter); EZPW (rotated out by dynamic screener/volatili...
August 25, 2026 at 8:54 PM
fundspec.bsky.social
Xencor ($XNCR) reported EPS of -0.29 beating estimate of -0.83 for Q2 2026. Revenue 51.2 Million Vs 17.166888 Million expected.
https://fundspec.ai
Build custom AI trading models for XNCR with the FundSpec App!
August 5, 2026 at 8:45 PM
signalbloom.ai
Xencor Beats Q2 Estimates on One-Time Royalty Payment as Operating Losses Widen https://signalbloom.ai/news/XNCR/xencor-beats-q2-estimates-on-one-time-royalty-payment-as-operating-losses-widen $XNCR #Earnings via @signalbloom.ai
August 5, 2026 at 8:05 PM
stocktitan.net
#XNCR Xencor Reports Second Quarter 2026 Financial Results

https://www.stocktitan.net/news/XNCR/xencor-reports-second-quarter-2026-financial-2faotvn2ugj6.html
Xencor Reports Second Quarter 2026 Financial Results
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026.. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned...
www.stocktitan.net
August 5, 2026 at 8:01 PM
ravionwire.bsky.social
$XNCR 🤝

Xencor entered into a settlement agreement with Alexion to receive $105 million in two payments to resolve a commercial dispute over Ultomiris royalties.

Actionable market event
Agreement — $XNCR
July 29, 2026 at 8:07 PM
signalbloom.ai
Xencor Secures $105M Settlement with Alexion, Extends Cash Runway Through 2028 https://signalbloom.ai/news/XNCR/xencor-secures-105m-settlement-with-alexion-extends-cash-runway-through-2028 $XNCR #Earnings via @signalbloom.ai
July 29, 2026 at 8:08 PM
stocktitan.net
#XNCR Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

https://www.stocktitan.net/news/XNCR/xencor-to-receive-105-million-from-alexion-to-resolve-ultomiris-u-s-20sw07eqa61v.html
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor (NASDAQ: XNCR) agreed a Settlement Agreement with Alexion Pharma International Operations to resolve a commercial dispute over U.S. royalties on Ultomiris. Xencor will receive $105 million in two equal payments of $52.5 million, the first expected in August 2026 and the second on the one-year anniversary of the executed agreement. In return, Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris.According to Xencor, royalties on ex-U.S. sales of Ultomiris are expected to continue under the existing license terms. Xencor stated that this resolution restores its operating cash runway estimate through 2028 and that, based on current operating plans, it expects to have sufficient cash resources to fund research, development and operations through 2028. Updated guidance for year-end 2026 cash, cash equivalents and marketable debt securities will be provided with second-quarter 2026 financial results.
www.stocktitan.net
July 29, 2026 at 8:01 PM
spaceman-trading.bsky.social
Watchlist update (+9/-9)
Added: RYAM (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); FBRX (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); +7 more
Removed: XNCR (rotated out by dynamic screener/volatility filter); ELVA (rotated out by dynamic screener/volatili...
July 21, 2026 at 9:25 PM
spaceman-trading.bsky.social
Watchlist update (+9/-9)
Added: XNCR (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); RPD (dynamic screener passed volatility filter (ADR >=5.0% over 14d)); +7 more
Removed: IOVA (rotated out by dynamic screener/volatility filter); PBF (rotated out by dynamic screener/volatility...
July 20, 2026 at 8:30 PM
stocktitan.net
#XNCR Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

https://www.stocktitan.net/news/XNCR/xencor-announces-proffered-paper-oral-presentation-at-esmo-2026-for-gm9yvv87mmn5.html
Xencor Plans 2027 Pivotal Study of Kidney Cancer Therapy
Expansion cohorts are evaluating intravenous doses for the planned Phase 3 study in advanced kidney cancer; subcutaneous dose escalation continues, with the abstract available Oct. 18.
www.stocktitan.net
July 17, 2026 at 1:11 PM
openbionews.com
A daily synthesis of the 101 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-17. XNCR +16.86%, JSPR +14.34%, and ETON +13.79% led the upside on a clean ESMO 2026…

https://openbionews.com/analysis/daily-biotech-movers-2026-07-17/
August 6, 2026 at 9:55 PM
quant-hub.bsky.social
🚨 $XNCR
Feigal Ellen (Insider) reported special transactions (Non-P/S).
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
July 8, 2026 at 10:55 PM
quant-hub.bsky.social
🚨 $XNCR
Klencke Barbara (Insider) reported special transactions (Non-P/S).
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
July 8, 2026 at 10:55 PM
quant-hub.bsky.social
🚨 $XNCR
Montgomery Alan Bruce (Insider) reported special transactions (Non-P/S).
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
July 8, 2026 at 10:54 PM
quant-hub.bsky.social
🚨 $XNCR
SIMPSON TODD E (Insider) reported special transactions (Non-P/S).
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
July 8, 2026 at 10:52 PM
quant-hub.bsky.social
🚨 $XNCR
Deshaies Raymond Joseph (Insider) reported special transactions (Non-P/S).
SEC Filing: XNCR
Click to view the official SEC document.
www.sec.gov
July 8, 2026 at 10:52 PM